Travere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase Related to Commercial Manufacturing Scale-Up

Go back to Travere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase Related to Commercial Manufacturing Scale-Up
(NASDAQ: TVTX) Delayed: 66.07 +0.79 (1.21%)
Previous Close $65.28    52 Week High
Open $63.86    52 Week Low
Day High $66.54    P/E N/A 
Day Low $63.48    EPS
Volume 1,360,847